{"disease":{"id":"asthenia","name":"asthenia"},"drugs":{"marketed":[{"drug_id":"ravulizumab","indication_name":"Generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultomiris","generic_name":"RAVULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":75,"revenue":"5100","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells."},{"drug_id":"ravulizumab","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultomiris","generic_name":"RAVULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":75,"revenue":"5100","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells."},{"drug_id":"efgartigimod-alfa","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyvgart","generic_name":"EFGARTIGIMOD ALFA","company_name":"Argenx Bv","drug_phase":"marketed","molecular_target":"IgG receptor FcRn large subunit p51","drug_class":"Endoglycosidase [EPC]","quality_score":70,"revenue":"2500","mechanism":"Vyvgart works by binding to the p51 subunit of the FcRn receptor, preventing it from recycling antibodies back into the bloodstream."},{"drug_id":"efgartigimod","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Efgartigimod","company_name":"M. Peter Marinkovich","drug_phase":"marketed","molecular_target":"FcRn","drug_class":"Endoglycosidase [EPC]","quality_score":58,"revenue":"2500","mechanism":"Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability."},{"drug_id":"eptacog-alfa-activated","indication_name":"Glanzmann's thrombasthenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eptacog Alfa","generic_name":"EPTACOG ALFA (ACTIVATED)","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"distigmine","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ubretid","generic_name":"DISTIGMINE","company_name":"Torii Pharmaceuticals","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"distigmine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"azathioprine","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"neostigmine","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bloxiverz","generic_name":"NEOSTIGMINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Bloxiverz works by blocking the enzyme acetylcholinesterase, allowing more acetylcholine to be available in the nervous system."},{"drug_id":"eculizumab","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"rozanolixizumab-noli","indication_name":"Generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RYSTIGGO","generic_name":"ROZANOLIXIZUMAB-NOLI","company_name":"UCB INC","drug_phase":"marketed","molecular_target":"IgG receptor FcRn large subunit p51","drug_class":"Neonatal Fc Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"edrophonium","indication_name":"Diagnostic Test for Myasthenia Gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tensilon","generic_name":"EDROPHONIUM","company_name":"","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"ambenonium","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mytelase","generic_name":"AMBENONIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"ravulizumab-cwvz","indication_name":"Generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ULTOMIRIS","generic_name":"RAVULIZUMAB-CWVZ","company_name":"ALEXION PHARM","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ravulizumab-cwvz","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ULTOMIRIS","generic_name":"RAVULIZUMAB-CWVZ","company_name":"ALEXION PHARM","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ultomiris","indication_name":"Generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ultomiris","company_name":"Alexion Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ultomiris","indication_name":"Myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ultomiris","company_name":"Alexion Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"eculizumab-aeeb","indication_name":"Generalized Myasthenia Gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"soliris","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nipocalimab","indication_name":"Generalized Myasthenia Gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."},{"drug_id":"nipocalimab","indication_name":"generalized myasthenia gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."},{"drug_id":"nipocalimab","indication_name":"generalized myasthenia gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06820515","title":"ATHNdataset Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT06443333","title":"National, Multicentric Registry Study on Neuroimmunological Diseases in China","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT06617741","title":"Myasthenia Gravis Foundation of America Global MG Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3800,"lead_sponsor_name":"Myasthenia Gravis Foundation of America","has_results":false},{"nct_id":"NCT04176211","title":"The Impact of Myasthenia Gravis in the Real World","phase":"","overall_status":"COMPLETED","enrollment_count":2847,"lead_sponsor_name":"Vitaccess Ltd","has_results":false},{"nct_id":"NCT05219097","title":"The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis","phase":"","overall_status":"COMPLETED","enrollment_count":2663,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT04101578","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Da, Yuwei, M.D.","has_results":false},{"nct_id":"NCT03979521","title":"Burden of Disease in Myasthenia Gravis","phase":"","overall_status":"COMPLETED","enrollment_count":1680,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT07333196","title":"Tongji NADs Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1550,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07217509","title":"PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1500,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT06241521","title":"Myasthenia Gravis Registry in China","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT03205306","title":"Myasthenia Gravis and Psyche","phase":"","overall_status":"COMPLETED","enrollment_count":1399,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT06700616","title":"A Study in Patients With Myasthenia Gravis in China","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1199,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06259071","title":"MuSK Myasthenia 1000 Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Myasthenia Gravis Rare Disease Network","has_results":false},{"nct_id":"NCT06866483","title":"Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"ZS Associates","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT07022028","title":"Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia Gravis","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT03792659","title":"The EXPLORE MG Registry for Myasthenia Gravis","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT03905473","title":"Physical Activity and Fatigue in Myasthenia Gravis","phase":"","overall_status":"COMPLETED","enrollment_count":779,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05408702","title":"Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Institut de Myologie, France","has_results":false},{"nct_id":"NCT04535843","title":"Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04202341","title":"Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07247279","title":"Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04119908","title":"Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT04837625","title":"Study of Myasthenic Crisis in China","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT06898476","title":"Silkworm Pupa Powder Improves Dementia.","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Zhejiang Provincial Tongde Hospital","has_results":false},{"nct_id":"NCT05380128","title":"Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population","phase":"","overall_status":"COMPLETED","enrollment_count":297,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT05070858","title":"A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05694234","title":"Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06463587","title":"Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":264,"lead_sponsor_name":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT05556096","title":"Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":261,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06843044","title":"Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Valenta Pharm JSC","has_results":false},{"nct_id":"NCT04158661","title":"Influence of Minimally Invasive Thymectomy on the Subsequent Clinical Course of Myasthenia Gravis","phase":"","overall_status":"UNKNOWN","enrollment_count":248,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT04524273","title":"Myasthenia Gravis Inebilizumab Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":238,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05566964","title":"Descriptive Analysis of Real-world Data Collected with ME&MGopen","phase":"","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Ad scientiam","has_results":false},{"nct_id":"NCT07472777","title":"Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis","phase":"","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Beijing University of Chinese Medicine","has_results":false},{"nct_id":"NCT06743490","title":"Capturing Key MG-symptoms Using Smartphone Recordings.","phase":"","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05586789","title":"A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Valenta Pharm JSC","has_results":false},{"nct_id":"NCT06381284","title":"Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"ZS Associates","has_results":false},{"nct_id":"NCT05782049","title":"Ultrasound Characteristics of the Salivary Glands in Patients With Rheumatoid Arthritis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":210,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT06006832","title":"A Prospective Cohort Study of Myasthenia Gravis in China","phase":"","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06204042","title":"Multinational Glanzmann Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT03971422","title":"A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT07059871","title":"A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Zhejiang Hospital","has_results":false},{"nct_id":"NCT03613272","title":"The Curative Effect of Extended Thymectomy Performed Through Subxiphoid-right VATS Approach With Elevation of Sternum","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Jiang Fan","has_results":false},{"nct_id":"NCT04182984","title":"TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT04225871","title":"Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT04674605","title":"A Prospective Cohort Study Of Myasthenia Gravis","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT04951622","title":"A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":199,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT04963270","title":"A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}